Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Ann Surg Oncol. 2012 Aug;19(8):2494-9. doi: 10.1245/s10434-012-2311-9. Epub 2012 Apr 5.
To compare the short-term perioperative results and long-term oncologic outcomes between patients who underwent neoadjuvant chemoradiotherapy (NCRT) and patients who underwent postoperative adjuvant chemoradiotherapy (ACRT) for stage III rectal cancer.
From January 1997 to December 2008, a total of 47 patients who were diagnosed as clinical stage III rectal cancer followed by NCRT were matched according to age, gender, and operation method to 47 patients with pathologic stage III rectal cancer who underwent ACRT. Clinical characteristics, surgical and pathologic outcomes, postoperative complications and recovery, and oncologic outcomes were compared between the two groups.
There were no significant differences in demographics or preoperative characteristics between the NCRT and ACRT groups. Though more protective ileostomies were performed in the NCRT group, there was no statistical difference in operation times between the two groups. Patients in the NCRT group had a smaller tumor size (P < 0.001) and a smaller number of lymph nodes retrieved (P < 0.001). No differences were observed with respect to morbidity and recovery outcomes between the two groups. During the median 58-month follow-up periods, the NCRT group showed better disease-free survival and overall survival than the ACRT group (P = 0.002, P = 0.001, respectively).
NCRT in comparison to ACRT did not increase the risk of postoperative morbidity and provided better disease-free and overall survival in stage III rectal cancer patients.
比较接受新辅助放化疗(NCRT)和接受术后辅助放化疗(ACRT)的 III 期直肠癌患者的短期围手术期结果和长期肿瘤学结果。
1997 年 1 月至 2008 年 12 月,共 47 例临床诊断为 III 期直肠癌的患者接受 NCRT 治疗,根据年龄、性别和手术方式与 47 例接受 ACRT 的病理 III 期直肠癌患者进行匹配。比较两组患者的临床特征、手术和病理结果、术后并发症和恢复情况以及肿瘤学结果。
NCRT 和 ACRT 组在人口统计学或术前特征方面无显著差异。尽管 NCRT 组行保护性回肠造口术较多,但两组手术时间无统计学差异。NCRT 组肿瘤体积较小(P<0.001)和淋巴结检出数较少(P<0.001)。两组患者的发病率和恢复结果无差异。在中位 58 个月的随访期间,NCRT 组的无病生存率和总生存率均优于 ACRT 组(P=0.002,P=0.001)。
与 ACRT 相比,NCRT 并未增加术后发病率,并为 III 期直肠癌患者提供了更好的无病生存率和总生存率。